We describe a liquid-chromatographic method for simultaneous quantification of halopendol and its reduced metabolite in plasma and serum. Haloperidol and reduced haloperidol are concentrated from blood samples by liquid/liquid extraction into a hexane/isoamyl alcohol mixture, with chlorohalopendol as the internal standard. For chromatographic separation weused a reversed-phase cyano-bonded column and a mobile phase of pH 6.8 phosphate bufter/acetonitnle (55/45 by vol). Haloperidol and its reduced metabolite are detected electrochemically at +0.90 V potential between the working and reference electrodes. As little as 0.5 ng per injection is .detectable. Within-and between-day CVs for determinations of haloperidol and reduced haloperidol ranged from 4 to 7% each at a concentration of 10 1.rg/L. Halopendol concentrations measured by this method correlated well with those by gas-chromatography with nitrogensensitive detector and by radioimmunoassay. 
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HPLC Assay
Extraction of serum or plasma. Pipet 2 mL of patient's or control serum or heparinized plasma into disposable borosilicate culture tubes (16 x 125 mm) with Teflon-lined screw caps, already containing 20 jL of standard haloperidol and reduced haloperidol (both at a final concentration ranging from 1.0 to 40 g/L) and (or) the internal standard, chlorohaloperidol.
Prepare combined haloperidol and reduced haloperidol standards freshly each day by diluting a methanolic 1 g/L stock solution with the mobile phase to give final concentrations from 0.1 to 4.0 mg/L.
Mix the samples, let them stand for 5 mm, then add 250 iL of NaOH, 2 molfL, followed by 4 mL of the extraction solution: hexane/isoamyl alcohol (98.5/1.5, by vol). Vortexmix the tubes' contents three times for 1 mm each with a multi-tube vortex-type mixer and then centrifuge for 5 mm at 1000 x g. Transfer the clear (top) organic phases into a new set of tubes containing 1 mL of HC1, 0.2 mol/L. Repeat the extraction step on the aqueous (lower) phase once, then pool the organic phases of each sample by simply decanting them after freezing the aqueous phase on solid CO2. Vortexmix the pooled samples, centrifuge, and remove and discard the organic layers by gentle aspiration through Pasteur pipettes. Wash the remaining acid layers briefly with 2 mL of extraction solvent and alkalinize by adding 200 L of NaOH, 2 mol/L. Then re-extract the drugs into 2 mL of extraction solvent. Repeat this extraction step again, pool the resulting organic extracts in 10 x 75 mm borosilicate glass tubes, and evaporate the extracts under a gentle stream of dry nitrogen at 45#{176}C. Seal the tubes and store overnight in the dark at -10 #{176}C. On the following day reconstitute the samples with 150 L of mobile phase and inject into the chromatograph.
Samples are fully stable under these storage conditions for at least three days, with no interconversion of the drugs observed during the extraction or storage steps. Parallel measurements of haloperidol and reduced haloperidol concentrations in serum and plasma samples taken simultaneously from five patients gave respectively identical results. The same extraction procedure can also be used for urine and brain samples (brain tissue is homogenized in water before the extraction).
Chromatographic apparatus.
The HPLC system consisted of a Waters 6000A pump (Waters Associates, Milford, MA 01757), a manual Valco injection valve equipped with a 100-L sample loop, and a LC-4A amperometric detector with a glassy carbon TL-5 flow cell (Bioanalytical Systems Inc., West Lafayette, IN 47906). The detector was operated at +0.90 V potential between the working electrode and the Ag/AgC1 reference electrode at a sensitivity of 10 nA fullscale deflection. The colunm (Bondapak CN, 3.9 x 30 cm, 1O-jnn particle size, Waters Associates) was kept at a temperature of 30#{176}C with an aluminum column jacket and a water circulator. Chromatograins were recorded with a Kipp and Zonen BD9 two-channel recorder operated at 1-and 10-V full scale.
Mobile phase and conditioning of the column.
Mobile phase is prepared freshly every day. It consists of preffitered (through 0.45-.tm HA-filters; Millipore, Bedford, MA 01730) potassium phosphate buffer, 40 mmolIL (adjusted to pH 6.8 with 5 mol/L KOH) and HPLC-grade acetonitrile, 55/45 (by vol). The mobile phase is constantly bubbled with helium gas to stabilize the baseline by decreasing the amount of dissolved air (13).
The nitrile-bonded jBondapak CN columns are initially washed (50-100 mL each wash) with doubly distilled water, then with sodium acetate buffer (50 mmol!L, pH 4.8), followed by acetonitrile in the acetate buffer (40/60, by vol). Potassium phosphate is then introduced to the column at a low concentration (5 mmollL, pH 4.8) and then finally equilibrated with the mobile phase described above.
Calculation of results. Peak heights in the chromatograms
were measured manually. Concentrations of haloperidol and reduced haloperidol were assessed by using the slope of the standard curve for peak-height ratios for the analytes and the internal standard.
Comparison Methods

Gas-chromatography of haloperidol.
The GC method for haloperidol was modified from Foreman et al. In brief, serum samples (2 to 4 mL) were extracted according to the same procedure as described in the HPLC assay, except that flurazepam served as an internal standard (40 ng per assay tube); the extraction solvent was hexane/isoamyl alcohol (98/2, by vol), and all solutions were transferred by Pasteur pipettes without freezing the tubes. Evaporated residues were reconstituted with the extraction solution, and 10 L was injected into the GC system. A Hewlett-Packard 5880A gas chromatograph equipped with a nitrogen-phosphorus detector and a glass column (2 m x 2 mm, i.d.) packed with 3% OV-17 on GasChrom-Q 100/120 mesh (Alltech Associates, Inc., Deerfield, IL 60015) were used. The instrument was operated with the following temperature program: initial temperature 220 #{176}C at 0 mm, rate 20 #{176}C/min up to 3.5 mm, final temperature 290 #{176}C maintained for 10 mm. Helium was used as a carrier gas (flow rate, 30 mLfmin) with hydrogen (3 mL/min) and air (60 mb/mm) as detector gases. The retention times of haloperidol and flurazepam were 5.5 and 4.4 nun, respectively. The detection limit of the assay (peak height 3 x noise) was 1 ng of haloperidol per injection.
Radioimmunoassay of haloperidol.
The RIA procedure for haloperidol was modified from Poland and Rubin (9). Haloperidol was extracted from 0.5-mL aliquots of serum or plasma, after addition of [3Hjhaloperidol (2000 dpm inS L) as an internal standard for the extraction step and 100 L of 2 mol/L NaOH, with 5 mL of the HPLC extraction solvent. The organic phase, separated from the aqueous phase by freezing the aqueous phase on solid C02, was decanted and evaporated under a gentle stream of nitrogen. The residue was reconstituted in aqueous methanol (300 mLfL) to its original volume. Analytical recovery of the extraction step, 80 ± 13% (mean ± SD, n = 41), was assessed by comparing [3H]haloperidol radioactivity before and after the extraction.
In general, duplicate 50-FL aliquots of the extract were diluted first with 0.5 mL of pH 7.5 buffer containing, per liter, 0.2 mol of phosphate, 0.3 g of sodium azide, and 20 g of fatty-acid-free BSA. Rabbit antiserum raised against BSAconjugated haloperidol (9) was diluted 300-fold in this phosphate buffer and a 0.1-mL aliquot was added to each tube. Finally, we added 50 1zL of [3Hlhaloperidol (30 000 dpm) in aqueous methanol, 300 mLfL. To construct the standard curve we used 50-FL aliquots of standard haloperidol solutions (0.05 to 4 ng/50 L) in the aqueous methanol. All tubes were tightly capped, vortex-mixed, and incubated in the dark at 25#{176}C with shaking overnight. The next day, all tubes were cooled at 4#{176}C for 30 to 40 mm. To each tube 0.2 mL of a charcoal-dextran suspension in the phosphate buffer (20 g of charcoal and 2 g of dextran per liter) was added. The contents of the tubes were vortex-mixed, left to stand at 4#{176}C for 30 mm, and finally centrifuged at 800 x g at 4#{176}C for 10 mm. After decanting the supernates into glass liquid scintillation vials and mixing with 1 mL of water and 10 mL of Aquassure, we counted their radioactivity in a Model LS-9000 liquid scintillation counter (Beckman Instruments, Fullerton, CA 92634), correcting the counts for quenching by external standardization.
To measure total radioactivity we prepared duplicate tubes containing only 0. The sensitivity of the assay (i.e., the amount of haloperidol that decreased the initial binding ability by at least 10%) was 0.05 ng per assay tube. The mean interassay and intra-assay CVs for repeated measurements of a serum pool containing 40 ng of haloperidol per milliliter were about 9 and 7%, respectively. Of the major metabolites of haloperidol, only the reduced haloperidol produced a minimal but measurable interference at high concentrations. The ratio of reduced haloperidol concentration to haloperidol concentration that displaced [3Hllhaloperidol binding to antibody by 50% was 300; no interference by reduced haloperidol was detected at 50 zig/mb.
Results and Discussion
Chromatographic Conditions Figure 2 shows the separation of haloperidol, reduced haloperidol, and chlorohalopendol. Although the drugs were separated on either nitrile-bonded (&Bondapak CN) or C18-bonded (Bondapak C18) columns, the lesser polarity of the C18-bonded columns caused each of the drugs to be more strongly retained; in addition, some late-eluting impurities were obtained with C 18-bonded columns. For these reasons, we used nitrile-bonded columns routinely for the separations.
Detector sensitivity decreased as the pH of the mobile phase was decreased from neutrality to about 4.5. The CNcolumns retained butyrophenones less efficiently and lost selectivity at low mobile-phase pH values; in addition, unknown peaks from extracted sera interfered with the separation of the drugs under these conditions. It is also known that mtrile-bonded phases degrade at pH values higher than neutrality. For these reasons, a mobile-phase pH value of 6.8 was chosen for further development of the method. Unknown substances in drug-free sera were eluted before the butyrophenones at pH 6.8, if the acetonitrile concentration in the mobile phase was at least 400 mIiL. No other substances co-eluted with the butyrophenones in drugfree samples.
Voltage profiles of haloperidol, reduced haloperidol, and chlorohaloperidol obtained with the system are shown in Figure 3 . An electrode potential of +0.90 V provided maxiElectrode potential, mV mum sensitivity for the assay. Although the structural differences among the three compounds are relatively small, the voltage profiles differ considerably.
Further electrochemical studies should be carried out to ascertain the relationship between molecular structure and electrochemical response.
Assay Characteristics
Precision.
Reproducibility
of the method was assessed by analyzing four to five replicate samples taken on each of six different days from two serum pools. Equal concentrations of haloperidol and reduced haloperidol (about 2 or 10 tg/L) were added to the serum pools. Chiorohaloperidol served as an internal standard at a concentration of 15 j.tgfL. As shown in Table 1 , when the drug concentrations were 2 ug/L (i.e., a concentration slightly higher than the detection limit of the assay), the coeffIcients of variation (CVs) are doubled. Reproducibilities were comparable for haloperidol and reduced haloperidol. The CVs calculated at the higher drug concentration agree well with the CVs obtained by other methods, including GC and HPLC with ultraviolet detection (3-7) . Maximum intra-and interassay CVs obtained in RIA exceed the CV observed with this method at the lower haloperidol concentration (9) . Accuracy. The absolute recoveries of haloperidol (10 g/ L), reduced haloperidol (10 gfL), and chiorohaloperidol (15 zg/L) were 92 ± 3, 93 ± 3, and 81 ± 2% (mean ± SD, n = 14), respectively. The standard curve was linear with butyrophenone concentrations up to 120 rgtL (Figure 4) . Table 2 compares results of haloperidol determinations by HPLC, GC, and RIA in patients' samples. In general, the mean values obtained with each method are comparable. The value of Pearson's correlation coefficient for the HPLC and the GC results was 0.78 (p < 0.02) and for the HPLC and the RIA results 0.76 (p <0.02).
Sensitivity.
Haloperidol and reduced haloperidol could be detected by the HPLC assay with equal sensitivity. The detection limit (i.e., peak height equal to 3 x baseline noise) was 0.5 ng, allowing routine measurements of 1-2 g/L in a 2-mb serum or plasma sample and 0.25 to 0.5 gIL in a 4-mL sample volume. Thus, the sensitivity of the HPLC method was lower than that of RIAs, but about the same as that of GC and GC/mass spectrometric methods (14).
Interference from Other Drugs
The retention times of several psychotropic compounds (100 ng each) injected into the HPLC system are compared in Table 3 . Interferences can be expected in samples from Anticholinergics, however, which are most commonly used in combination with haloperidol, do not interfere with the assay. Although other drugs may not co-elute with haloperidol, the sensitive electrochemical detector can be overloaded if several drugs are present in the sample. This is a genuine concern, because the concentrations of haloperidol in blood are quite low as compared with those of other psychotropic drugs currently in use.
As can be seen from We have described an HPLC method with the sensitivity, precision, and accuracy necessary for clinical monitoring of haloperidol concentrations and for pharmacological investigations of haloperidol metabolism. In addition, the method allows for the simultaneous quantitation of reduced haloperidol, a potentially psychoactive metabolite of haloperidol. The basic and clinical pharmacology of reduced haloperidol is still poorly understood, even though this compound seems to be a major metabolite of haloperidol in man. For example, although haloperidol steady-state concentrations in serum correlated with the daily dose (r = 0.80, p < 0.02), a similar correlation with reduced haloperidol was much weaker (r = 0.58, p> 0.09) ( Table 2 ). In addition, using the same HPLC method, we have observed about equally high concentrations of haloperidol and reduced haloperidol in human postmortem brain tissue obtained from patients who had a history of haloperidol treatment (Korpi, Costakos, and Kleinman, unpublished). These observations underscore the need to measure reduced haloperidol concentrations in clinical research studies of haloperidol metabolism. The present HPLC method for haloperidol is equivalent in sensitivity and precision to GC methods. RIAs are more sensitive, but they appear to be less precise than the HPLC assay. In addition, HPLC (and GC) analyses can be automated after the extraction step. Hence, haloperidol concentrations in blood of psychiatric patients can be conveniently measured by high-performance liquid chromatography with electrochemical detection, but lower haloperidol concentrations such as those present in cerebrospinal fluid may necessitate the use of an RIA procedure. The main advantage of the HPLC method is that it allows for the simultaneous determination of haloperidol and reduced haloperidol concentrations.
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